Condition

Non-small Cell Lung Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 1,161 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials1,161

Recruiting157

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)NCT07541170 · 2026-09-30

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCNCT07777822 · 2026-08-14

Barriers and Facilitators of Persistence With Adjuvant OsimertinibNCT07542210 · 2026-08-13

Effects of Infusion Timing on Treatment Response in Solid TumorsNCT07630168 · 2026-08-03

A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)NCT07642024 · 2026-07-24

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)NCT07554339 · 2026-06-18

A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid TumorsNCT07623369 · 2026-06-11

Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.NCT07279935 · 2026-05-26

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A TrialNCT07382726 · 2026-05-15

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)NCT07513376 · 2026-05-04

3D Virtual Resection for Predicting Lung Function in VATSNCT07436598 · 2026-04-07

Septum-guided Segmentectomy for Deep Early-stage Lung Cancer (SGS2512)NCT07564557 · 2026-04-01

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid TumorsNCT07589205 · 2026-03-31

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)NCT07431827 · 2026-03-18

Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsNCT07104630 · 2026-03-16

IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary ImmunotherapyNCT07608835 · 2026-02-12

Precise Exercise Regimen for Cancer Care (PERCC): A Pilot StudyNCT07412041 · 2026-01-22

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsNCT07195695 · 2026-01-16

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerNCT06686771 · 2025-12-16

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung CancerNCT07229729 · 2025-11-24

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerNCT06899126 · 2025-10-24

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)NCT07190248 · 2025-10-08

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)NCT07111520 · 2025-09-22

Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung CancerNCT07150663 · 2025-08-20

A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid TumorsNCT07056556 · 2025-07-30

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043 · 2025-07-29

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung CancerNCT07086456 · 2025-07-20

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCNCT06765109 · 2025-07-17

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung CancerNCT06877299 · 2025-07-04

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLCNCT06745882 · 2025-06-13

Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerNCT06903377 · 2025-05-23

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced MalignanciesNCT07064018 · 2025-04-30

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)NCT06731907 · 2025-03-30

Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative StudyNCT06567704 · 2025-03-26

Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung CancerNCT06930807 · 2025-03-25

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual DiseaseNCT06529822 · 2025-03-20

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line TreatmentNCT06841055 · 2025-03-03

The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)NCT06861543 · 2025-03-01

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)NCT06838273 · 2025-02-24

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)NCT06809764 · 2025-02-21

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845 · 2025-01-14

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung CancerNCT06712316 · 2025-01-07

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal MetastasisNCT06643000 · 2024-12-20

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced CancersNCT06422403 · 2024-11-25

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738 · 2024-11-18

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid TumorsNCT06612840 · 2024-10-16

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal CancersNCT06562192 · 2024-10-15

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386 · 2024-10-07

Carbon Ion Therapy for Peripheral Non-small Cell Lung CancerNCT05613452 · 2024-09-29

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerNCT06463665 · 2024-09-26

A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsNCT06561685 · 2024-09-19

A Study of VET3-TGI in Patients With Solid TumorsNCT06444815 · 2024-09-16

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsNCT06586515 · 2024-09-12

Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World DataNCT06934343 · 2024-09-01

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICINCT06388031 · 2024-08-09

Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly PatientsNCT06311981 · 2024-08-08

Anesthesia and Non-small Cell Lung Cancer RecurrenceNCT06330038 · 2024-08-05

Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRINCT06545747 · 2024-08-01

A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerNCT06498986 · 2024-07-31

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069 · 2024-07-01

Common interventions

Leading sponsors

Sun Yat-sen University 41 AstraZeneca 31 Merck Sharp & Dohme LLC 24 Eli Lilly and Company 22 Hunan Province Tumor Hospital 18 Betta Pharmaceuticals Co., Ltd. 17 Sichuan Baili Pharmaceutical Co., Ltd. 15 Novartis Pharmaceuticals 13 Samsung Medical Center 13 Massachusetts General Hospital 12 Pfizer 12 Daiichi Sankyo 10 Fudan University 10 M.D. Anderson Cancer Center 10 Shanghai Pulmonary Hospital, Shanghai, China 10

Trial status mix

COMPLETED407

UNKNOWN284

RECRUITING157

TERMINATED152

ACTIVE_NOT_RECRUITING90

WITHDRAWN41

NOT_YET_RECRUITING21

SUSPENDED4

NO_LONGER_AVAILABLE3

ENROLLING_BY_INVITATION1

TEMPORARILY_NOT_AVAILABLE1

Phase mix

PHASE2550

PHASE1313

PHASE3144

NA97

PHASE416

EARLY_PHASE15

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.